

SKYEPHARMA PLC
Form 6-K
March 14, 2006

**SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of March, 2006

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

For Immediate Release

Edgar Filing: SKYEPHARMA PLC - Form 6-K

SkyePharma PLC

Agreement with Major Shareholders Over Selection of Non-Executive Directors

LONDON, UK, 14 March 2006 - SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) announces that following ("EGM") held on 9 March, at which a shareholder resolution to appoint a new director was n agreement with two of its major institutional investors over arrangements for the selection a non-executive directors acceptable to both the Company and those institutions.

Dr Jerry Karabelas, SkyePharma's Non-Executive Chairman, said: "Although SkyePharma strive corporate governance, there is always room for improvement. We have noted the level of dissati significant body of shareholders. We are happy to have reached agreement over a process that the satisfaction of all. We can now concentrate on the primary task of execution of the Compan believe will benefit all shareholders."

Anita Skipper, Head of Corporate Governance for Morley Fund Management, said: "The Company and looking to work constructively with shareholders following the EGM. We welcome the steps the continuing the dialogue."

William Claxton-Smith, Director, Investor Responsibility at Insight Investment Management, sa are happy that our initial aim of strengthening the Board of SkyePharma will be achieved. We will

For further information please contact:

SkyePharma PLC

Frank Condella, Chief Executive Officer

Peter Laing, Director of Corporate Communications

+44 207 491 1777

+44 207 491 5124

Sandra Houghton, US Investor Relations

+1 212 753 5780

Buchanan Communications

Tim Anderson / Mark Court

+44 207 466 5000

Notes for editors:

About SkyePharma

SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery te and more effective drug formulations. There are now eleven approved products incorporating Skye oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabi www.skyepharma.com.

Certain statements in this news release are forward-looking statements and are made in reliance U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectatio statements are reasonable, it can give no assurance that these expectations will materialize. B risks and uncertainties, actual results may vary significantly from those expressed or impli based upon a number of factors, which are described in SkyePharma's 20-F and other documents on cause differences between actual results and those implied by the forward-looking statements c without limitation, risks related to the development of new products, risks related to obtainin for existing, new or expanded indications of existing and new products, risks related to SkyePh on a large scale or at all, risks related to SkyePharma's and its marketing partners' ability maintain or expand market share in the face of changes in customer requirements, competition an to regulatory compliance, the risk of product liability claims, risks related to the ownership risks related to SkyePharma's ability to manage growth. SkyePharma undertakes no obliga forward-looking statement to reflect events or circumstances after the date of this release.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ Douglas Parkhill

Name: Douglas Parkhill

Title: Company Secretary

Date: March 14, 2006